* The study investigated the effects of aldafermin, a new treatment, through a meta-analysis of four randomized controlled trials involving 491 patients, focusing on its efficacy and safety at different doses (1 mg and 3 mg).
* Results indicated that aldafermin significantly reduced liver fat and enzyme levels in a dose-dependent manner, although it did not show marked differences in certain histological and metabolic outcomes, with mild side effects primarily noticing increased diarrhea at the higher dose.